Company: CNTB
Filing Date: 2025-07-22
Form Type: 8-K
Source: 0001835268-25-000047
Chunk: 0

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-07-22
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 22, 2025, the Board of Directors (the “ Board”) of Connect Biopharma Holdings Limited (the “ Company”), upon the recommendation of its Nominating and Corporate Governance Committee (the “ Nominating Committee”), increased the size of the Board from six (6) to seven (7) directors and appointed James A. Schoeneck to fill the vacancy so created, effective immediately. The Board expects to appoint Mr. Schoeneck to one or more Board committees at a later date.

Mr. Schoeneck, age 67, served as Chief Executive Officer of Depomed, Inc. (DEPO), a commercial specialty pharmaceutical company, from 2011 until 2017, and joined the Board of Directors of Depomed in 2007. From 2005 until 2011, he was Chief Executive Officer of BrainCells, Inc., a privately-held biopharmaceutical company. Prior to joining BrainCells, Inc., he served as Chief Executive Officer of ActivX BioSciences, Inc., a development-stage biotechnology company. Mr. Schoeneck’s pharmaceutical experience also includes three years as President and Chief Executive Officer of Prometheus Laboratories Inc., a pharmaceutical and diagnostics products company. Prior to joining Prometheus, Mr. Schoeneck spent three years as Vice President and General Manager, Immunology, at Centocor Inc. (now Janssen Biotech, Inc.), a biotechnology company, where he led the development of Centocor’s commercial capabilities. Earlier in his career, he spent 13 years at Rhone-Poulenc Rorer Inc. (now Sanofi), a pharmaceutical company, serving in various sales and marketing positions of increasing responsibility. Mr. Schoeneck currently serves as an independent director and Chairman of the Board of Directors of each of FibroGen, Inc. (FGEN) and Calidi Biotherapeutics, Inc. (CLDI). In addition, from 2015 to 2018, he served on the Board of Directors of AnaptysBio, Inc. (ANAB). Mr. Schoeneck also previously served as Chairman of the National Board of Directors of the Asthma and Allergy Foundation of America. Mr. Schoeneck holds a B. S. from Jacksonville State University.

Mr. Schoeneck will participate in and receive compensation for his service on the